One of the few bright spots in Boston’s life-science lab space market this year has dimmed.

Return on Assets (ROA): Ginkgo Bioworks Holdings's ROA lags behind industry averages, suggesting challenges in maximizing ...

Ginkgo Bioworks (DNA) delivered earnings and revenue surprises of 55% and 102.77%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Ginkgo Bioworks is headquartered at 27 Drydock Avenue in Boston's Seaport. Ginkgo has canceled its planned move into a ...

In a recent transaction, Steven P. Coen, the Chief Accounting Officer of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA), sold shares of the company's stock, reportedly to cover tax ...

Ginkgo Bioworks Holdings, Inc. , which is building the leading platform for cell programming and biosecurity, today announced its results for the third quarter ended September ...

BASEL, Switzerland - Syngenta Crop Protection and Ginkgo Bioworks announced a partnership aimed at expediting the development and commercialization of a new biological solution for ...

New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast ... Rayonier Adv Materials and Ginkgo Bioworks ...

In a report released today, Tejas Savant from Morgan Stanley maintained a Buy rating on Guardant Health (GH – Research Report), with a ...

XWELL delivered 2024 third quarter revenue growth of approximately 13% from the comparable quarter in 2023. Additionally, for the nine-month period ended September 30, 2024, XWELL delivered revenue ...